In adults with mixed dyslipidaemia, a 400 mg dose of the ANGPTL3 siRNA, solbinsiran, significantly reduced ANGPTL3 over 270 days, together with significant reductions in apoB, and TG. These were the key findings of the Phase 2 PROLONG-ANG3 trial, presented by Professor Kausik Ray, (Imperial College London, UK) at ACC.25, and published simultaneously in The Lancet.1,2
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
